Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy in platinum-failed advanced head and neck squamous cell carcinoma
ChiCTR1900022204Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Hospital of Jilin University. Primary endpoint: overall survival. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR1900022204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022204.